Attenuation of dopamine-induced renal vasodilation in the dog by phenothiazines.
D000818:Animals; D001920:Bradykinin / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology*; D018492:Dopamine Antagonists; D005260:Female; D005476:Fluphenazine / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D008297:Male; D010640:Phenothiazines / Q000494:pharmacology*; D011346:Prochlorperazine / Q000494:pharmacology; D011955:Receptors, Drug; D012039:Regional Blood Flow / Q000187:drug effects; D012077:Renal Artery / Q000187:drug effects*; D013881:Thioridazine / Q000494:pharmacology; D014268:Trifluoperazine / Q000494:pharmacology; D014665:Vasodilator Agents
D018492:Dopamine Antagonists; D010640:Phenothiazines; D011955:Receptors, Drug; D014665:Vasodilator Agents; D014268:Trifluoperazine; D006220:Haloperidol; D013881:Thioridazine; D005476:Fluphenazine; D001920:Bradykinin; D002746:Chlorpromazine; D004298:Dopamine; D011346:Prochlorperazine